Eppendorf experts discuss regulatory challenges, single-use technologies, and digitalization strategies for scaling from R&D to commercial manufacturing.

Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess (R) enterprise ...

The continuous manufacturing market offers key growth opportunities in streamlining pharmaceutical production by reducing costs, minimizing downtime, and enhancing product quality. The market is ...

Ireland’s biopharmaceutical sector continues to thrive amid key financial incentives, proximity to key markets, and favorable regulatory frameworks.

Researchers based in Germany have developed a perfusion process for the manufacture of oncolytic viruses. The team from the Max Planck Institute says that the new approach aims to improve virus titers ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsRainer Blair - President, CEO ...

Leerink Global Healthcare Conference 2026 March 10, 2026 11:20 AM EDTCompany ParticipantsJason Garland - CFO & ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Kelun-Biotech (6990.HK) today ...

The SCIEX Echo MS+ and ZenoTOF 8600 systems redefine screening with one-second acoustic sampling and 10x sensitivity. By removing LC bottlenecks, this label-free platform accelerates drug discovery ...

In February 2026, the solid-state battery industry accelerated its transition from pilot-scale trials to mass production, with sulphide electrolytes becoming the primary technological focus, and the ...

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

If there was any lingering doubt about what’s keeping Big Oil executives up at night, the fourth-quarter results cleared it up. It’s not slogans. It’s not transition optics. It’s whether they have ...